Method of inhibiting fibrinogen binding to endothelial cells with fibrinogen gamma chain peptides
US5919754A · kind A · utility
5Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 1996 |
| Grant date | Jul 6, 1999 |
| Priority date | — |
| Expiry date | Nov 12, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.